Research at ProSci
ProSci Research
ProSci Incorporated specializes in the functions of antibodies and the production of affinity-purified peptide-specific polyclonal antibodies to novel antigens in fields such as HIV. To date, ProSci has an antibody catalog of over 20,000 antibodies. Many of the polyclonal research antibodies offered by ProSci are affinity-purified, which allows for the isolation of antibodies specific to the epitope of interest. As a result, ProSci's antibodies have the same specificity as monoclonal antibodies at a price below our competitors' polyclonal antibodies. In addition, ProSci offers a complete assortment of immunochemistry technologies, including cell lysates, tissue lysates and peptides to complement the use of these antibodies.
In conjunction with its strengths in the antibody and reagent market, ProSci Incorporated actively conducts research in a variety of fields. Most notably, ProSci is performing research in fields such as HIV vaccine development. Here are ProSci publications and grants awarded...
Vaccine: August 2015
Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans. Hong Zhang, Hu Fu, Robert J. Luallen, Bingfen Liu, Fang-Hua Lee, Robert W. Doms, Yu Geng
HIV Glycans in infection and Immunity: 2013
Anti-Carbohydrate HIV Vaccine Design. Lai-Xi Wang, Paolo Costanino, Yu Geng, Hong Zhang
Journal of Virology: January 2011
Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. Caroline Agrawal0Gamse, Robert J. Luallen, Bingfen Liu, Hu Fu, Fang-Hua Lee, Yu Geng, Robert W. Doms
Glycobiology: March 2010
Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains. Robert J Luallen, Caroline Agrawal-Gamse, Hu Fu, David F. Smith, Robert W. Doms, Yu Geng
Journal of Virology: May 2009
A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. Robert J. Luallen, Hu Fu, Caroline Agrawal-Gamse, Innocent Mboudjeka, Wei Huang, Fang0Hua Lee, Lai-Xi Wang, Robert W. Doms, Yu Geng
Journal of Virology: July 2008
An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. Robert J. Luallen, Jianqiao Lin, Hu Fu, Karen K. Cai, Caroline Agrawal, Innocent Mboudjeka, Fang-Hua Lee, David Montefiori, David F. Smith, Robert W. Doms, Yu Geng
Our ongoing research programs demonstrate ProSci’s expertise on the functions of antibodies and role as a leader in the scientific community. Through these projects, ProSci scientists have advanced their antibody development methods.
NIH SBIR
Grant # 1 R43 CA90119-01 Date issued: 1/18/2001
Grant # 1 R43 AI51903-01 Date issued: 5/27/2002
Grant # 1 R43 AI058724-01A2 Date issued: 4/25/2006
Grant # 1 R43 AI078829-01 Date issued: 1/30/2008
Grant # 1 R43 AI112484-01A1 Date issued: 6/26/2014
IAVI Innovartion Fund Date issued: 5/19/2009
IRS QTDP Date issued: 10/29/2010
By using ProSci Inc, researchers reduce research expenses, gain access to indispensable customer support to ensure the proper use and function of their antibodies, and incorporate quality products into the research process. Our expertise in using these products and services for research purposes enables us to provide the customer with detailed and relevant advice concerning the use of antibody and immunochemistry technologies. We look forward to providing you with our outstanding products and services.